Lancet

Article	Citations
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019	7735
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis	5061
Endothelial cell infection and endotheliitis in COVID-19	4776
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission	4706
Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019	3968
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK	3639
RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study	3144
Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis	2675
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial	2561
Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic	2227
Gastric cancer	2076
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial	1928
Hyperinflammatory shock in children during COVID-19 pandemic	1795
An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study	1748
Alzheimer's disease	1614
Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study	1572
Pancreatic cancer	1376
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational	1322
Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study	1289
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia	1281
Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants	1276
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study	1265
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 tr	1265
Parkinson's disease	1253
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	1246

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study	1235
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial	1128
Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study	1118
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial	1088
Non-alcoholic fatty liver disease	1085
Global estimates of the need for rehabilitation based on the Global Burden of Disease study 2019: a systematic analysis for the Global Burden of Disease Study 2019	1083
Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic	1026
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial	1009
The 2020 report of The Lancet Countdown on health and climate change: responding to converging crises	970
Sex and gender: modifiers of health, disease, and medicine	968
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-	947
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial	943
Lung cancer	940
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study	924
Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21	919
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials	909
Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global	893
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study	882
Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment	855
SARS-CoV-2 and viral sepsis: observations and hypotheses	851
SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness	848
Atopic dermatitis	834
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study	832
Psoriasis	821
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials	819
COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study	818
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia	774
Chronic pain: an update on burden, best practices, and new advances	768
Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression	754
Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study	751
Breast cancer	733
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label	719
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial	697
Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence	694
1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study	686
The 2021 report of the Lancet Countdown on health and climate change: code red for a healthy future	685
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study	684
Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling study	674
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey	663
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study	657
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial	641
Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry	635
Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series	630
Fertility, mortality, migration, and population scenarios for 195 countries and territories from 2017 to 2100: a forecasting analysis for the Global Burden of Disease Study	628
Ten scientific reasons in support of airborne transmission of SARS-CoV-2	620
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (	616
Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burd	610
Offline: COVID-19 is not a pandemic	605
Hepatocellular carcinoma	590
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial	574

COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study	566
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial	564
Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the Z	558
Stroke	555
The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030	547
Liver cirrhosis	542
Lessons learnt from easing COVID-19 restrictions: an analysis of countries and regions in Asia Pacific and Europe	540
Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (ARREST): a phase 2, single centre, open-label, randomised controlled trial	533
SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)	530
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial	529
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial	526
Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study	523
Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss	522
Hot weather and heat extremes: health risks	506
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled,	506
Oxford–AstraZeneca COVID-19 vaccine efficacy	504
COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England	498
Chronic kidney disease	497
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial	492
Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	492
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial	488
Immune checkpoint inhibitors in melanoma	488
SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates	486
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis	486
Male infertility	473
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination	464
Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study	458
Gout	453
Nociplastic pain: towards an understanding of prevalent pain conditions	451
Acute pancreatitis	447
The 2022 report of the Lancet Countdown on health and climate change: health at the mercy of fossil fuels	446
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial	445
Acute respiratory distress syndrome	444
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial	441
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed	440
SARS-CoV-2 variants and ending the COVID-19 pandemic	436
Biliary tract cancer	436
Low back pain	431
Bipolar disorders	429
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial	425
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial	424
Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination	422
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo	417
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis	412
Endometriosis is a chronic systemic disease: clinical challenges and novel innovations	411
Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019	410
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial	406
Iron deficiency	406
Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study	403
Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study	388
Quality of primary health care in China: challenges and recommendations	384
Retinal findings in patients with COVID-19	380
Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study	377
Pre-eclampsia	377
RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis	376
Hearing loss prevalence and years lived with disability, 1990–2019: findings from the Global Burden of Disease Study 2019	372
Irritable bowel syndrome	371
Osteoarthritis in 2020 and beyond: a Lancet Commission	369
Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised cont	368
Kawasaki-like disease: emerging complication during the COVID-19 pandemic	365
Multiple myeloma	360
Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021	359
Endometrial cancer	357
Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals	351
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial	348
Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study	346
Global, regional, and national prevalence estimates of physical or sexual, or both, intimate partner violence against women in 2018	345
Ethnicity and COVID-19: an urgent public health research priority	345
Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial	344
Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2	342
Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial	339
SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials	337
COVID-19 in Brazil: “So what?”	335
Spike-antibody waning after second dose of BNT162b2 or ChAdOx1	335
Obesity could shift severe COVID-19 disease to younger ages	335
Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis	335
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study	330
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives	326
Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenS	326
Cystic fibrosis	325

The Lancet Commission on lessons for the future from the COVID-19 pandemic	324
The Lancet Commission on the future of care and clinical research in autism	323
COVID-19: the case for health-care worker screening to prevent hospital transmission	323
Time for united action on depression: a Lancet–World Psychiatric Association Commission	320
Migraine: epidemiology and systems of care	317
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised	316
Five insights from the Global Burden of Disease Study 2019	314
Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial	312
The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study	309
Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study	308
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial	306
Artificial intelligence and the future of global health	302
WHO International Standard for anti-SARS-CoV-2 immunoglobulin	302
Schizophrenia	301
Head and neck cancer	301
Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study	300
Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum	293
Revisiting maternal and child undernutrition in low-income and middle-income countries: variable progress towards an unfinished agenda	289
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label,	289
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-grou	285
The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019	285
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial	283
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cel	282
Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial	279
Impacts of COVID-19 on childhood malnutrition and nutrition-related mortality	277
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial	275
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 stu	275
The first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study	275
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials	274
Considering BCG vaccination to reduce the impact of COVID-19	273
Guillain-Barré syndrome	272
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial	272
Detection of SARS-CoV-2 in human breastmilk	272
COVID-19: PCR screening of asymptomatic health-care workers at London hospital	270
Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials	269
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controll	267
Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine	266
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial	265
Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose	265
Extracorporeal membrane oxygenation for COVID-19: evolving outcomes from the international Extracorporeal Life Support Organization Registry	265
The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality	264
Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial	263
Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study	263
Venous thromboembolism	263
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study	260
Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial	258
Fragmented health systems in COVID-19: rectifying the misalignment between global health security and universal health coverage	258
Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study	257
Considerations in boosting COVID-19 vaccine immune responses	256
Body-mass index and obesity in urban and rural China: findings from consecutive nationally representative surveys during 2004–18	255
Chronic pancreatitis	252
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial	252
Prostate cancer	251
Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients	251
Chronic obstructive pulmonary disease	247
Challenges for the female academic during the COVID-19 pandemic	245
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial	243
SARS-CoV-2 renal tropism associates with acute kidney injury	242
Sputnik V COVID-19 vaccine candidate appears safe and effective	242
Association of metabolic–bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 part	241
From race-based to race-conscious medicine: how anti-racist uprisings call us to act	240
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, ac	239
First experience of COVID-19 screening of health-care workers in England	237
Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical tr	237
Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study	235
Functional dyspepsia	235
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis	234
Estimating global and regional disruptions to routine childhood vaccine coverage during the COVID-19 pandemic in 2020: a modelling study	233
Wearing face masks in the community during the COVID-19 pandemic: altruism and solidarity	232
Diagnostics for COVID-19: moving from pandemic response to control	232
Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemic	231
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications	227
Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial	227